AIM:N-acetyltransferase 2 (NAT2) is an important enzyme catalyzingN-acetylation of sulfasalazine (SASP). The aim of the present study was to investigate associations of the genotypes ofNAT2with inflammatory bowel disease (IBD), and with adverse effects of SASP, which is used as the first-line treatment of IBD.PATIENTS AND METHODS: The wildtype allele (NAT2*4) and three variant alleles (NAT2*5B, NAT2*6AandNAT*7B) of theNAT2gene were determined in 101 patients with IBD (84 patients with ulcerative colitis and 17 patients with Crohn’s disease) and 109 healthy controls by the polymerase chain reaction-restriction fragment length polymorphism method. Sixty-eight patients with IBD treated with SASP were followed, and their adverse reactions were recorded.RESULTS: Eleven patients (16%) experienced adverse effects from SASP, including nine cases of sulfapyridine (SP) dose-related adverse effects and two cases of hypersensitivity (skin rash). Patients with the slow acetylator genotypes without theNAT2*4allele experienced adverse effects more frequently (36%) than those with the fast acetylator genotypes with at least oneNAT2*4allele (11%), but the results were not significantly different (OR of 0.26, 95% CI 0.065 to 1.004; P=0.051). However, those with the slow acetylator genotypes experienced more SP dose-related adverse effects than those with the fast acetylator genotypes (36% versus 8%, OR of 0.17, 95% CI 0.039 to 0.749; P=0.019).CONCLUSIONS: TheNAT2gene polymorphism was not associated with susceptibility to IBD in Chinese populations, but theNAT2slow acetylator genotypes were significantly associated with SP dose-related adverse effects of SASP in the treatment of IBD.
